Sanofi and Regeneron Report Phase 3 Results for Dupixent in Eosinophilic Esophagitis

Sanofi and Regeneron today announced Phase 3 trial results for Dupixent (dupilumab) in patients with eosinophilic esophagitis (EoE). The trials met their primary endpoints, demonstrating significant reductions in esophageal eosinophil counts and improvements in dysphagia symptom scores compared to placebo. These results led to FDA approval of Dupixent for EoE, making it the first biologic approved for this condition.